FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385856386> ?p ?o ?g. }

• W4385856386 endingPage "e1182717" @default.
• W4385856386 startingPage "e1182717" @default.
• W4385856386 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Chronic myelomonocytic leukaemia (CMML) is a clonal haematopoietic stem cell malignancy, and allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option. The outcomes after transplant are influenced by both disease- and patient-related factors. Aims: Develop a novel prognostic model to predict post-transplant survival for CMML patients. Methods: A prognostic model was developed from the univariable and multivariable Cox proportional hazards regression models. Results: The analysis included 218 CMML patients treated with allo-HSCT from 27 centres in China from 2005 to 2022. We identified risk factors by applying univariable and multivariable Cox proportional hazards regression to a derivation cohort of 119 patients. In multivariable analysis, advanced age (hazard ratio [HR] 3.583), leukocyte count (HR 3.499) and anaemia (HR 3.439) at initial diagnosis, bone marrow blast cell count before transplant (HR 2.095), and no cGVHD after transplant (HR 4.799) were independently associated with worse survival. Accordingly, a novel prognostic model termed ABLAG (Age, Blast, Leukocyte, Anaemia, cGVHD) was developed based on the regression equation, and the following points were assigned: 1 point for age > 60 years, blasts > 10%, leukocyte counts > 32×109/L or haemoglobin≤120 g/L and 2 points for no cGVHD. The CMML prognostic model (range, 0-6) was predictive of survival and non-relapse mortality (NRM) (P<0.001 for both), and the patients were stratified into 3 risk groups: low risk (0-1), intermediate risk (2-3), and high risk (4-6). Three risk groups were identified, with a 3-year survival of 93.3% for low risk, 78.9% for intermediate risk, and 51.6% for high risk (P<0.001) and a 3-year NRM of 6.1% for low risk, 17.3% for intermediate risk, and 36.8% for high risk (P<0.001). An increasing risk score was also significantly associated with lower progression free survival (PFS) (P <0.001); however, there was no difference in the cumulative relapse rate among the three risk groups (P=0.077). Then, we evaluated the performance of the prognostic model through a bootstrap procedure for internal validation. Furthermore, an external validation with data from a validation cohort consisting of 99 patients from 1 other centre was conducted. The areas under the receiver operating characteristic (ROC) curves for the derivation and validation cohort were 0.829 (95% CI, 0.776-0.902) and 0.749 (95% CI, 0.684-0.854), respectively. Both calibration plots showed that the novel model illustrated a high degree of consistency in the estimated and observed risk compared with existing models designed for the non-transplant setting. Moreover, we generated a decision curve analysis curve to determine whether the model could provide a clinical benefit for CMML patients after allo-HSCT. Compared with previous prognostic scoring models, the novel prognostic model contributed to considerable net benefits. Conclusion: In conclusion, by combining disease- and patient-related factors, this novel CMML prognostic model provides better survival stratification for patients with CMML receiving allo-HSCT and may facilitate personalized counselling. Keywords: Allogeneic hematopoietic stem cell transplant, Prognostic, Chronic myelomonocytic leukemia" @default.
• W4385856386 created "2023-08-17" @default.
• W4385856386 creator A5001433537 @default.
• W4385856386 creator A5001508669 @default.
• W4385856386 creator A5002188808 @default.
• W4385856386 creator A5004465845 @default.
• W4385856386 creator A5005371991 @default.
• W4385856386 creator A5011029344 @default.
• W4385856386 creator A5013296641 @default.
• W4385856386 creator A5016048028 @default.
• W4385856386 creator A5018709756 @default.
• W4385856386 creator A5019762150 @default.
• W4385856386 creator A5020289063 @default.
• W4385856386 creator A5024762725 @default.
• W4385856386 creator A5030664078 @default.
• W4385856386 creator A5033694430 @default.
• W4385856386 creator A5038357890 @default.
• W4385856386 creator A5041108474 @default.
• W4385856386 creator A5041591591 @default.
• W4385856386 creator A5043041637 @default.
• W4385856386 creator A5044988420 @default.
• W4385856386 creator A5046175512 @default.
• W4385856386 creator A5046348283 @default.
• W4385856386 creator A5046424825 @default.
• W4385856386 creator A5049242358 @default.
• W4385856386 creator A5050562004 @default.
• W4385856386 creator A5051211027 @default.
• W4385856386 creator A5052368006 @default.
• W4385856386 creator A5056446917 @default.
• W4385856386 creator A5060211823 @default.
• W4385856386 creator A5061407928 @default.
• W4385856386 creator A5061664113 @default.
• W4385856386 creator A5062370040 @default.
• W4385856386 creator A5064161818 @default.
• W4385856386 creator A5065894155 @default.
• W4385856386 creator A5066523722 @default.
• W4385856386 creator A5067347223 @default.
• W4385856386 creator A5067783564 @default.
• W4385856386 creator A5068216415 @default.
• W4385856386 creator A5069229404 @default.
• W4385856386 creator A5069358812 @default.
• W4385856386 creator A5069852316 @default.
• W4385856386 creator A5070538645 @default.
• W4385856386 creator A5071212122 @default.
• W4385856386 creator A5072208411 @default.
• W4385856386 creator A5076024438 @default.
• W4385856386 creator A5077666079 @default.
• W4385856386 creator A5078195113 @default.
• W4385856386 creator A5078632164 @default.
• W4385856386 creator A5080036092 @default.
• W4385856386 creator A5081663648 @default.
• W4385856386 creator A5087610827 @default.
• W4385856386 date "2023-08-01" @default.
• W4385856386 modified "2023-10-18" @default.
• W4385856386 title "P1277: IMPACT OF A NOVEL PROGNOSTIC MODEL ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH CMML" @default.
• W4385856386 doi "https://doi.org/10.1097/01.hs9.0000971996.11827.17" @default.
• W4385856386 hasPublicationYear "2023" @default.
• W4385856386 type Work @default.
• W4385856386 citedByCount "0" @default.
• W4385856386 crossrefType "journal-article" @default.
• W4385856386 hasAuthorship W4385856386A5001433537 @default.
• W4385856386 hasAuthorship W4385856386A5001508669 @default.
• W4385856386 hasAuthorship W4385856386A5002188808 @default.
• W4385856386 hasAuthorship W4385856386A5004465845 @default.
• W4385856386 hasAuthorship W4385856386A5005371991 @default.
• W4385856386 hasAuthorship W4385856386A5011029344 @default.
• W4385856386 hasAuthorship W4385856386A5013296641 @default.
• W4385856386 hasAuthorship W4385856386A5016048028 @default.
• W4385856386 hasAuthorship W4385856386A5018709756 @default.
• W4385856386 hasAuthorship W4385856386A5019762150 @default.
• W4385856386 hasAuthorship W4385856386A5020289063 @default.
• W4385856386 hasAuthorship W4385856386A5024762725 @default.
• W4385856386 hasAuthorship W4385856386A5030664078 @default.
• W4385856386 hasAuthorship W4385856386A5033694430 @default.
• W4385856386 hasAuthorship W4385856386A5038357890 @default.
• W4385856386 hasAuthorship W4385856386A5041108474 @default.
• W4385856386 hasAuthorship W4385856386A5041591591 @default.
• W4385856386 hasAuthorship W4385856386A5043041637 @default.
• W4385856386 hasAuthorship W4385856386A5044988420 @default.
• W4385856386 hasAuthorship W4385856386A5046175512 @default.
• W4385856386 hasAuthorship W4385856386A5046348283 @default.
• W4385856386 hasAuthorship W4385856386A5046424825 @default.
• W4385856386 hasAuthorship W4385856386A5049242358 @default.
• W4385856386 hasAuthorship W4385856386A5050562004 @default.
• W4385856386 hasAuthorship W4385856386A5051211027 @default.
• W4385856386 hasAuthorship W4385856386A5052368006 @default.
• W4385856386 hasAuthorship W4385856386A5056446917 @default.
• W4385856386 hasAuthorship W4385856386A5060211823 @default.
• W4385856386 hasAuthorship W4385856386A5061407928 @default.
• W4385856386 hasAuthorship W4385856386A5061664113 @default.
• W4385856386 hasAuthorship W4385856386A5062370040 @default.
• W4385856386 hasAuthorship W4385856386A5064161818 @default.
• W4385856386 hasAuthorship W4385856386A5065894155 @default.
• W4385856386 hasAuthorship W4385856386A5066523722 @default.
• W4385856386 hasAuthorship W4385856386A5067347223 @default.
• W4385856386 hasAuthorship W4385856386A5067783564 @default.
• W4385856386 hasAuthorship W4385856386A5068216415 @default.
• W4385856386 hasAuthorship W4385856386A5069229404 @default.

• next